Sana'a: The Public Health and Population Committee of the Parliament convened a meeting chaired by Khalid al-Ansi, with government representation from the Minister of Health and Environment, Dr. Ali Shaiban, to discuss the draft law on clinical pharmaceutical studies. The meeting included participation from Mohammed Suwar, Chairman of the Development and Oil Committee, Osama Omar, rapporteur of the Constitutional Committee, and Mohammed al-Junaid, rapporteur of the Media, Culture, and Tourism Committee.
According to Yemen News Agency, the draft law aims to set scientific foundations and standards for medical studies and research. It seeks to encourage researchers, establish research centers for clinical pharmaceutical studies, and promote the localization of pharmaceutical industries. The committee emphasized the urgency of finalizing the draft law, with the Speaker of the House showing keen interest in its swift completion.
Khalid al-Ansi highlighted the importance of integrating observations from the draft law discussions, considering all implications of its implementation. The importance of adhering to scientific competence, accurate research, and internationally recognized medical protocols was stressed. The committee also discussed the division of clinical pharmaceutical studies into four phases, from initial human studies to large-scale volunteer groups, ensuring the safety and efficacy of medical interventions.
The committee underscored the need for continuous monitoring of pharmaceutical products and adherence to ethical standards in all research. The Minister of Health and Environment pointed out the draft law's role in achieving high scientific standards for medical research, inviting the House of Representatives' Committee to visit the Bioequivalence Center at Sana'a University to observe its operations.